Naslov
Efficacy and drug tolerability of preservative- free latanoprost-timolol fixed combination in glaucoma and ocular hypertension patients with existing ocular surface disease switched from the preserved prostaglandin analog-timolol fixed combinations

Autori
Jandroković, Sonja ; Vidas Pauk, Sania ; Lešin Gaćina, Dina ; Škegro, Ivan ; Tomić, Martina

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Book of abstracts of the 15th EGS Congress / - , 2022, 49-49

Skup
15th EGS Congress

Mjesto i datum
Atena, Grčka, 04.06.2022. - 08.06.2022

Vrsta sudjelovanja
Pozvano predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
prostaglandin analog-timolol fixed combinations ; preservatives, preservative-free, drug tolerability

Sažetak
Purpose: To evaluate the effect of switching the preserved prostaglandin analog-timolol fixed combinations (PG-timolol FCs) to preservative-free latanoprost-timolol FC [T2347 (Fixalpost®) Laboratories Théa, Clermont Ferrand, France] on intraocular pressure (IOP) lowering efficacy and the local drug tolerability in glaucoma and ocular hypertension (OH) patients, with concurrent ocular surface disease (OSD). Methods: Longitudinal, prospective, interventional study of drug tolerability and efficacy – a real life study. The data from 36 patients, mean age 67.14 ± 7.78 years, were collected and analyzed between March 2021 and September 2021. Patients were switched from preserved latanoprost, travoprost, or bimatoprost with timolol FCs to preservative-free latanoprosttimolol FC (PF-LT) on the baseline visit. Patients were examined on days 1, 30, and 90. At each visit all the participants underwent Goldman applanation tonometry, assessment of the extent and severity of OSD symptoms by using Ocular Surface Disease Index (OSDI) Questionnaire, assessment of conjunctival hyperemia by using the McMonnies-Chapman-Davies scale, assessment of the blepharitis by using the Efron’s scale, and the eyelids and periocular hyperemia assessment. Registers: Primary ClinicalTrials.gov Identifier: NCT04891588, Secondary DRKS - German Clinical Trials Register, DRKS-ID: DRKS00024581. Results: Significant reduction in overall median IOP has been shown on the second visit (day 30), which remained stable to the third visit (day 90) (16 vs. 14 vs. 14 mmHg, p < 0.001). Also, significant improvements were demonstrated in OSD symptoms (median OSDI score 27.1 vs. 9.6 vs. 4.2, p < 0.001) and signs, conjunctival hyperemia (2 vs. 1 vs. 1, p < 0.001), blepharitis (2 vs.1 vs. 1, p < 0.001), and eyelid and periocular hyperemia (61.1 vs. 12.5 vs. 2.8 %, p < 0.001), form baseline to the second and the third visits. Conclusion: Switching from preserved PG-timolol FCs to PF-LT (Fixalpost®) significantly reduced symptoms and signs of OSD, improved ocular drug tolerability, and consequently quality of life with effective reduction of intraocular pressure

Izvorni jezik
Engleski

POVEZANOST RADA